The global generic drugs industry, which experienced solid growth over the last five years, is expected to continue its momentum to reach an estimated $335 billion in 2017 with a CAGR of 6.5% over the next five years. Increasing government efforts to reduce healthcare costs, patent expirations of blockbuster drugs, and rising incidence of chronic diseases are expected to drive the demand for generic drugs during the forecast period.
Lucintel, a leading global management consulting and market research firm, has analyzed the global generic drugs industry and presents its findings in “Global Generic Drugs Industry 2012-2017: Trend, Profit, and Forecast Analysis.”
The industry comprises firms primarily engaged in the development, manufacture, and marketing of generic drugs. The generic segment includes generic drugs from all therapeutic areas including central nervous system drugs, cardiovascular drugs, oncology drugs, and all such generic drugs. The industry is fragmented and affected by government regulations in different regions and countries.
As the study indicates, cost effectiveness and increasing awareness have increased the demand for generic drugs. Stringent regulatory approval processes, price control measures for generic drugs, and increasing export barriers are some of the challenges for the industry.
Asia Pacific (APAC) is forecast to witness the highest growth over 2012-2017 and North America will remain the largest market during forecast period. Transformation in the healthcare sector and desire to control costs are anticipated to boost generic drugs use in North America.
Lucintel’s study provides an overview of the global generic drugs industry and tracks industry performance in four geographic regions. The report studies manufacturers and distributors of generic drugs, providing a five-year annual trend analysis that highlights market size, profit and cost structure for North America, Europe, APAC, and the Rest of the World. The report also provides a forecast, addressing market opportunities for each of these regions.
This comprehensive guide from Lucintel provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the market’s potential. This report will save Lucintel clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global generic drugs industry analysis. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis.
To make any investment or strategic decision, you need adequate and timely information. This market report fulfills this core need. Some of the features of this market report are:
• Industry size estimates in terms of (US $) value by regions
• Global generic drugs industry analysis annual trend (2006-2011) and forecast (2012-2017)
• Porter’s Five Force analysis
• New product launch and merger and acquisition activity in global generic drugs industry analysis
• Quarterly demand trend (Q1 2010-Q4 2011) and forecast analysis (Q1 2012-Q4 2013) for global generic drugs industry analysis
• Gross and net profit trends in the global generic drugs industry analysis
• Cost structure trend in the global as well as regional generic drugs industry analysis
• More than 44 valuable figures/charts and 11 tables are provided in this report